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Dear Editor, 
As an indicator of long-term glycemic control in pa-
tients with diabetes mellitus (DM), glycosylated hemo-
globin (HbA1c) has proved to be superior over fasting 
blood sugar as a reliable and a more accurate measure of 
diabetes treatment [1]. Although the clinical implications 
of HbA1c have been highlighted by widely cited guidelines 
in relation to the microvascular complications of DM [2], 
the role of HbA1c in predicting cardiovascular (CV) out-
come is being cumulatively investigated [3].
An increasing body of knowledge supports the inde-
pendent and linear association of HbA1c level and the se-
verity of atherosclerotic peripheral arterial disease (PAD) 
[4, 5], the literature has taken the prognostic value of HbA1c 
to the next level, i.e., predicting the incidence of macrovas-
cular diseases in nondiabetic individuals [3, 5, 6].
The timely publication of the paper by Ambrosi et al. 
[7] in a recent issue of Cardiology highlights a valuable 
standpoint for clinical trials of antidiabetic drugs to con-
sider HbA1c as a predictive measure for the CV benefits 
of the new medications being tested. As this meta-analy-
sis concludes, mean decrease in HbA1c is directly corre-
lated with a reduction in major CV events. Furthermore, 
such a relationship is independent of the weight loss ob-
served during the study period of the included clinical 
trials. We sought to provide a few perspectives from 
which this research study could be interpreted more prac-
tically. 
This meta-analysis could have drawn a clearer picture 
of the history of DM-related CV complications at the 
baseline for each of the included clinical trials. While 
there might have been a lack of information at the indi-
vidual level, the frequency of CV disease of any type at the 
time of enrollment has been depicted for each trial and it 
ranged from 41 to 100% of the patients. If provided, 
the relationship between post-treatment HbA1c alteration 
and the de novo incidence of CV complications of DM 
would be much clearer. 
Although the change in HbA1c was correlated with the 
change in CV events at the end of the follow-up period, 
the duration of follow-up was not highlighted in the me-
ta-analysis. Previous studies have shown the clinical util-
ity of HbA1c as a predictor of short-term mortality after 
acute coronary syndrome, and it also bears prognostic 
value for long-term CV complications of lesser severity. 
In either case, more elaboration on the follow-up period 
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during which the incidence of CV events was measured 
against the net change in HbA1c would have expanded 
our concept of its time-sensitive predictive value.
Interestingly, the relative change in the major CV 
events between the new antidiabetic drug and placebo 
ranged from –3 to 26% compared to the unidirectional 
change in HbA1c percentage. A sensitivity analysis ex-
cluding these outliers would shed a brighter light on the 
relationship between HbA1c and CV events. 
The meta-analysis by Ambrosi et al. [7] truly high-
lights the easing role of a universally accepted marker as 
a surrogate for the prediction of CV outcomes in clinical 
trials of antidiabetic drugs. However, the above-men-
tioned points can widen our perspectives from which this 
clinical surrogate is viewed by investigators of future re-
search studies.
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